ArticleInternational journal of clinical and experimental pathology2015
MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Exosome therapeutics for non-small cell lung cancer tumorigenesis.Cancer cell international · 2024Review
- Review
- Review
- Prognostic risk assessment model and drug sensitivity analysis of colon adenocarcinoma (COAD) based on immune-related lncRNA pairs.BMC bioinformatics · 2022Article
- CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer.Advanced pharmaceutical bulletin · 2022Review
- Overview of CaExploration of targeted anti-tumor therapy · 2021Review
- Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells.Molecular medicine reports · 2020Article
- Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1.Signal transduction and targeted therapy · 2020Article
- MicroRNA-34c-3p target inhibiting NOTCH1 suppresses chemosensitivity and metastasis of non-small cell lung cancer.The Journal of international medical research · 2020Article
- The Promise of next generation sequencing micro RNA for the discovery of new targets in contrast induced acute kidney injury.Annals of translational medicine · 2019Article
- Retracted Article: Structural characterization ofRSC advances · 2019Article
- Tumor-educated platelet miR-34c-3p and miR-18a-5p as potential liquid biopsy biomarkers for nasopharyngeal carcinoma diagnosis.Cancer management and research · 2019Article
- Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells.Molecular therapy. Nucleic acids · 2018Article
- miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer.Oncology letters · 2018Article
- Identification of cancer-related miRNA-lncRNA biomarkers using a basic miRNA-lncRNA network.PloS one · 2018Article
- MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer.Cell proliferation · 2017Review
- Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer.Journal of thoracic disease · 2017Article
- MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer.Oncology letters · 2017Article
- miRNA-34c inhibits myoblasts proliferation by targeting YY1.Cell cycle (Georgetown, Tex.) · 2017Article
- Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs have become recognized as key players in the development of malignancy. They are a family of small non-coding RNAs (22 nt~30 nt) that can negatively regulate the expression of cancer-related genes by sequence selective targeting of mRNAs, leading to either mRNA translational repression or degradation. Lung cancer is the leading cause of cancer-related death worldwide with a substantially low survival rate. In this study, we analyzed the expression profile of miR-34c-3p in non-small cell lung cancer (NSCLC) tissues and cell lines, as its participation in some other types of cancer has been shown by previous reports. We found that miR-34c-3p was downregulated both in NSCLC tissues and cell lines. Overexpression of miR-34c-3p suppressed cell proliferation and colony formation and also limited migration and invasion in A549 cells. Furthermore, our results also shown miR-34c-3p reduction was associated with increased PAC1 expression levels in which miR-34c-3p downregulated PAC1 expression by recognizing and binding to specific binding sites in PAC1 3'-UTR. Taken together, our study implicates important roles of miR-34c-3p in NSCLC pathogenesis and implicates its potential application in cancer therapy.
Indexed as
Identifiers
26261507PMC4525841W1168474682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.